Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 - 60 Years: A “Campus CML” Study

Blood (2024) 144 (Supplement 1): 1772.

https://doi.org/10.1182/blood-2024-207175

Published: 2024

Journal Articles

Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

Blood (2024) 144 (Supplement 1): 4535.

https://doi.org/10.1182/blood-2024-202477

Published: 2024

Journal Articles

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study

Blood (2024) 144 (Supplement 1): 4532.

https://doi.org/10.1182/blood-2024-211476

Published: 2024

Journal Articles

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2023-186406

Published: 2023

Journal Articles

Treatment-Free Remission in Ponatinib-Treated CML Patients: The Italy-Tfr Experience

Carmen Fava, Marco Santoro, Marianna Caramella, Elisabetta Abruzzese, Valentina Giai, Daniele Cattaneo, Chiara Elena, Mario Tiribelli, Mariella D'Adda, Giuseppina Loglisci, Valentina Bonuomo, Selene Grano, Jacqueline Ferrari, Federica Maria Catania, Ester Maria Pungolino, Alessandra Iurlo

Blood (2023) 142 (Supplement 1): 6385.

https://doi.org/10.1182/blood-2023-187230

Published: 2023

Journal Articles

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Blood (2022) 140 (Supplement 1): 3920–3922.

https://doi.org/10.1182/blood-2022-164790

Published: 2022

Journal Articles

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

Blood (2021) 138 (Supplement 1): 1487.

https://doi.org/10.1182/blood-2021-149780

Published: 2021

Journal Articles

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study

Blood (2021) 138 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2021-151538

Published: 2021

Journal Articles

Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML"

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-135972

Published: 2020

Journal Articles

Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141077

Published: 2020

Journal Articles

Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a “Real-life” Patient Population With Chronic Myelogenous Leukemia?

Roberto Latagliata, MD, Ida Carmosino, Federico Vozella, Paola Volpicelli, MD, Giuseppina Loglisci, Michelina Santopietro, Adriano Salaroli, MD, Angela Romano, Chiara Montagna, Amanda Roberto, Alessandra Serrao, Daniela Diverio, PhD, Mauro Nanni, PhD, Marco Mancini, Agostino Tafuri, Massimo Breccia, Giuliana Alimena, MD

Blood (2013) 122 (21): 4002.

https://doi.org/10.1182/blood.V122.21.4002.4002

Published: 2013

Journal Articles

FLT3-ITD Internal Tandem Duplication Confers Poor Prognosis In Patients With Acute Promyelocytic Leukemia Treated With The AIDA Protocols. Long-Term Follow-Up Analysis

Massimo Breccia, Giuseppina Loglisci, MD, Maria Giovanna Loglisci, Phd, Roberto Ricci, Daniela Diverio, PhD, Roberto Latagliata, MD, Robin Foà, Francesco Lo Coco, MD

Blood (2013) 122 (21): 1336.

https://doi.org/10.1182/blood.V122.21.1336.1336

Published: 2013

Journal Articles

Delayed Cytogenetic Response and Reduced Rate of Major Molecular Response Associated to Increased Body Mass Index At Baseline in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib.

Massimo Breccia, Giuseppina Loglisci, MD, Adriano Salaroli, MD, Alessandra Serrao, MD, Paola Volpicelli, MD, Daniela Diverio, PhD, Roberto Latagliata, MD, Giuliana Alimena

Blood (2012) 120 (21): 2784.

https://doi.org/10.1182/blood.V120.21.2784.2784

Published: 2012

Journal Articles

Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib

Paola Volpicelli, MD, Roberto Latagliata, MD, Massimo Breccia, Federico Vozella, Paola Finsinger, Ida Carmosino, Giuseppina Loglisci, MD, Michelina Santopietro, MD, Adriano Salaroli, Daniela Diverio, PhD, Marco Mancini, MD, Agostino Tafuri, Giuliana Alimena

Blood (2012) 120 (21): 3769.

https://doi.org/10.1182/blood.V120.21.3769.3769

Published: 2012

Journal Articles

Long-Term Follow-up of Chronic Phase Chronic Myeloid Leukemia Patients Who Failed Interferon Alpha and Switched to Imatinib

Massimo Breccia, Giuseppina Loglisci, MD, Adriano Salaroli, MD, Alessandra Serrao, MD, Irene Zacheo, MD, Roberto Latagliata, MD, Giuliana Alimena

Blood (2012) 120 (21): 3742.

https://doi.org/10.1182/blood.V120.21.3742.3742

Published: 2012

Journal Articles

Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols

Massimo Breccia, Luca Mazzarella, Vincenzo Bagnardi, Davide Disalvatore, Giuseppina Loglisci, Giuseppe Cimino, Anna Maria Testi, Giuseppe Avvisati, Maria Concetta Petti, Clara Minotti, Roberto Latagliata, Robin Foà, Pier Giuseppe Pelicci, Francesco Lo-Coco

Blood (2012) 119 (1): 49–54.

https://doi.org/10.1182/blood-2011-07-369595

Published: 2012

Journal Articles

Increased Body Mass Index Correlates with Higher Risk of Disease Relapse and Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia Treated with Aida Protocols

Massimo Breccia, MD, Luca Mazzarella, MD, Giuseppina Loglisci, Vincenzo Bagnardi, Davide Disalvatore, Roberto Latagliata, Anna Maria Testi, Giuseppe Cimino, MD, Giuseppe Avvisati, MD, Maria Concetta Petti, Pier Guiseppe Pelicci, Robin Foá, MD, Francesco Lo Coco

Blood (2011) 118 (21): 4866.

https://doi.org/10.1182/blood.V118.21.4866.4866

Published: 2011

Journal Articles

Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,

Roberto Latagliata, Massimo Breccia, Ida Carmosino, Federico Vozella, Paola Volpicelli, Antonietta Ferretti, Giuseppina Loglisci, MD, Michelina Santopietro, Vincenzo Federico, Rosa De Cuia, Daniela Diverio, Mauro Nanni, PhD, Marco Mancini, Giuliana Alimena

Blood (2011) 118 (21): 3783.

https://doi.org/10.1182/blood.V118.21.3783.3783

Published: 2011

Journal Articles

MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,

Massimo Breccia, Vincenzo Federico, Giuseppina Loglisci, Roberto Latagliata, Michelina Santopietro, Adriano Salaroli, Alessandra Serrao, Gioia Colafigli, Agostino Tafuri, Giuliana Alimena

Blood (2011) 118 (21): 3793.

https://doi.org/10.1182/blood.V118.21.3793.3793

Published: 2011

Journal Articles

An Observational Multicenter Study to Assess the Cost of Illness and Quality of Life in Patients with Myelodysplastic Syndromes in Italy

Valeria Santini, MD, Alessandro Sanna, MD, Alberto Bosi, MD, Giuliana Alimena, MD, Giuseppina Loglisci, MD, Alessandro Levis, MD, Flavia Salvi, MD, Carlo Finelli, MD, Cristina Clissa, MD, Giorgina Specchia, MD, Alessandra Ricco, MD, Agostino Cortelezzi, MD, Valeria Ferla, MD, Mariarita Sciumé, MD, Francesco Nobile, MD, Esther Oliva, MD, Carlo Lazzaro, EconD, Elisa Martelli, MSc

Blood (2011) 118 (21): 1023.

https://doi.org/10.1182/blood.V118.21.1023.1023

Published: 2011

NARROW

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 - 60 Years: A “Campus CML” Study

Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Treatment-Free Remission in Ponatinib-Treated CML Patients: The Italy-Tfr Experience

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study

Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML"

Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study

Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a “Real-life” Patient Population With Chronic Myelogenous Leukemia?

FLT3-ITD Internal Tandem Duplication Confers Poor Prognosis In Patients With Acute Promyelocytic Leukemia Treated With The AIDA Protocols. Long-Term Follow-Up Analysis

Delayed Cytogenetic Response and Reduced Rate of Major Molecular Response Associated to Increased Body Mass Index At Baseline in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib.

Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib

Long-Term Follow-up of Chronic Phase Chronic Myeloid Leukemia Patients Who Failed Interferon Alpha and Switched to Imatinib

Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols

Increased Body Mass Index Correlates with Higher Risk of Disease Relapse and Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia Treated with Aida Protocols

Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,

MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,

An Observational Multicenter Study to Assess the Cost of Illness and Quality of Life in Patients with Myelodysplastic Syndromes in Italy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only